Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying
Insider Transactions in Penny Stocks: Recent notable insider transactions include ARCA biopharma's 10% owner purchasing 220,083 shares at $3.18, Anixa Biosciences' director acquiring 5,000 shares at $3.09, Lifeloc Technologies' CFO buying 45,620 shares at $3.80, and Cyanotech's director purchasing 10,000 shares at $0.62.
Company Updates: ARCA biopharma reported a first-quarter loss of 14 cents per share; Anixa received FDA approval for its CAR-T therapy; Lifeloc appointed a new board member; and Cyanotech's net sales slightly decreased from fiscal 2023 to 2024.
Get Free Real-Time Notifications for Any Stock
Analyst Views on ANIX
About ANIX
About the author
Anixa Secures Mexican Patent for Breast Cancer Vaccine
- Patent Approval: Anixa Biosciences has received a patent allowance from the Mexican Institute of Industrial Property, marking an expansion of its international intellectual property coverage for breast cancer vaccine technology, thereby reinforcing its leadership in cancer immunotherapy.
- Market Opportunities: The patent complements existing patents in the U.S. and other key markets, laying the groundwork for Anixa's future regulatory and commercial efforts in regions with high breast cancer incidence like Mexico.
- Clinical Development Support: The vaccine is based on immunizing against human α-lactalbumin, aiming to selectively activate the immune system to prevent tumor formation, which is expected to improve breast cancer diagnosis and treatment outcomes for women in Mexico.
- Global Strategic Positioning: By strengthening its global patent estate, Anixa is paving the way for future international development and commercialization strategies, potentially partnering with larger pharmaceutical companies for worldwide commercialization.
Anixa Biosciences Declines Following Phase 1 Results for Breast Cancer Vaccine
Anixa Biosciences Phase 1 Trial Results: Anixa Biosciences (ANIX) reported a ~21% drop in stock after sharing phase 1 data for its breast cancer vaccine targeting α-lactalbumin, which showed that 74% of participants achieved immune responses.
Cohorts and Safety Findings: The trial involved 35 participants across three cohorts, with good safety and tolerability noted in the first two cohorts, while the third cohort experienced some Grade 3 adverse events related to injection-site irritation.
Future Trial Plans: Anixa indicated that the phase 2 trial design may include a combination study with Merck's Keytruda in the neoadjuvant setting for newly diagnosed breast cancer patients.
Market Reaction and Context: The market's reaction to the trial results has been cautious, with discussions around the justification of optimism regarding Anixa's upcoming phase 1 readout and other clinical programs.
